Catalyst Biosciences has raked in $40.4 million in third-round funding to continue engineering an enzyme called protease to fight disease-causing proteins. The technology has the potential to affect many different diseases, including cancer and hemophilia. It has R&D agreements with Wyeth Pharmaceuticals and Centocor Research & Development.

Based in South San Francisco, the company received its recent round from new investor Essex Woodlands Health Ventures and previous backers Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures and Sofinnova Ventures.